Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
54
self-reported 11–50 band
Founded
Not recorded
Registry matches
2
ABR
Office countries
1
1 address
Funding rounds
5
Post IPO equity · Jul 2024 · US$ 59.5M
Company type
Public Company
self-reported
Legal entities
1 brand → 2 possible registrationsThe join is a normalised name comparison against ABR. Treat every row below as a lead to verify, not as an established identity.
IMMUTEP LIMITED
ABN90009237889
IMMUTEP AUSTRALIA PTY LTD
ABN70154326566
Legal entities
Show as table · Immutep Limited: 2 registry entities
| IMMUTEP LIMITED | ABN 90009237889 |
|---|---|
| IMMUTEP AUSTRALIA PTY LTD | ABN 70154326566 |
| Confirmed matches | 0 of 2 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. Its lead clinical candidate in oncology is eftilagimod alfa, a proprietary soluble LAG-3 protein and MHC Class II agonist that activates the immune system to fight cancer. In autoimmune diseases, Immutep's IMP761 is the world's first LAG-3 agonist antibody designed to target the underlying causes of autoimmune diseases. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. For more information, please visit www.immutep.com.
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AULevel 33, Australia Square 264 George Street; Sydney, NSW 2000Primary
Grid intelligence Members
Funding
Last round · 4 July 2024US$ 59.5MPost IPO equity
Rounds5
Round typePost IPO equity · secondary transaction
Amount (USD)59,500,000
Stage rank6
Investors named0
Since last round1 yr 6 mo
Funding
Show as table · 5 funding rounds
| Rounds | 5 |
|---|---|
| Axis | 2025 to 2026 |
| Post IPO equity · 4 Jul 2024 | US$ 59.5M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
The people relation is never requested, so there is nothing here to unlock.
FAQ
Which legal entities operate under Immutep Limited?
Two New South Wales entities on the ABR: IMMUTEP LIMITED (ABN 90 009 237 889) and IMMUTEP AUSTRALIA PTY LTD (ABN 70 154 326 566). Both medium confidence.
How many people work at Immutep Limited?
54 counted staff profiles at January 2026, above the self-reported 11–50 band.
Where does Immutep Limited have offices?
One address on record, Australia only. Primary: Level 33, Australia Square 264 George Street, Sydney, NSW 2000.
Has Immutep Limited raised funding?
Five rounds. Latest 4 July 2024: post IPO equity, US$59,500,000.
Which companies are listed alongside Immutep Limited?
5 profiles list Immutep Limited as a peer — 62nd percentile in Biotechnology Research. It lists ten peers of its own. Imugene Limited and Noxopharm Limited list it back.